PE20030743A1 - Metodo para el tratamiento de trastornos oseos - Google Patents

Metodo para el tratamiento de trastornos oseos

Info

Publication number
PE20030743A1
PE20030743A1 PE2003000007A PE2003000007A PE20030743A1 PE 20030743 A1 PE20030743 A1 PE 20030743A1 PE 2003000007 A PE2003000007 A PE 2003000007A PE 2003000007 A PE2003000007 A PE 2003000007A PE 20030743 A1 PE20030743 A1 PE 20030743A1
Authority
PE
Peru
Prior art keywords
treatment
dose
maintenance
bone disorders
risandronate
Prior art date
Application number
PE2003000007A
Other languages
English (en)
Inventor
Pamela Jean Schofield
Den Berg Henry Nmn Van
David Ernest Burgio
Arkadi Aaron Chines
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23352430&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030743(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20030743A1 publication Critical patent/PE20030743A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN METODO PARA AUMENTAR LA MASA OSEA CON ALTA RENOVACION OSEA, REDUCCION DE FRACTURAS PARA EL TRATAMIENTO DE OSTEOPOROSIS QUE COMPRENDE ADMINISTRAR UNA DOSIS DE CARGA DURANTE 1 DIA A 180 DIAS DE UN BISFOSFONATO TAL COMO RISEDRONATO (15mg A 50mg), IBANDRONATO, PAMIDRONATO, ALENDRONATO (15mg A 70mg), CIMADRONATO, TILUDRONATO, ZOLENDRONATO, CLODRONATO, PIRIDRONATO; ADMINISTRAR DESPUES UNA DOSIS DE MANTENIMIENTO CONTINUA, SIENDO LA DOSIS DE CARGA DE DOS VECES A VEINTE VECES SUPERIOR A LA DOSIS DE MANTENIMIENTO, SEGUIDO POR UN REGIMEN DE DOSIFICIACION DE MANTENIMIENTO
PE2003000007A 2001-12-21 2003-01-06 Metodo para el tratamiento de trastornos oseos PE20030743A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34487501P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
PE20030743A1 true PE20030743A1 (es) 2003-10-22

Family

ID=23352430

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000007A PE20030743A1 (es) 2001-12-21 2003-01-06 Metodo para el tratamiento de trastornos oseos

Country Status (24)

Country Link
US (5) US20030118634A1 (es)
EP (1) EP1455796A1 (es)
JP (1) JP2005514400A (es)
KR (1) KR100638122B1 (es)
CN (1) CN100479823C (es)
AR (1) AR038041A1 (es)
AU (1) AU2002360619B2 (es)
CA (1) CA2469779C (es)
CZ (1) CZ2004690A3 (es)
HK (1) HK1087039A1 (es)
HU (1) HUP0402267A3 (es)
IL (2) IL162053A0 (es)
MA (1) MA27157A1 (es)
MX (1) MXPA04006027A (es)
MY (1) MY147886A (es)
NO (1) NO340249B1 (es)
NZ (1) NZ532994A (es)
PE (1) PE20030743A1 (es)
PL (1) PL371264A1 (es)
RU (1) RU2294203C2 (es)
SK (1) SK2532004A3 (es)
TW (1) TWI349553B (es)
WO (1) WO2003055496A1 (es)
ZA (1) ZA200404007B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100479823C (zh) * 2001-12-21 2009-04-22 宝洁公司 双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
NZ536273A (en) * 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
ATE475412T1 (de) * 2004-05-24 2010-08-15 Warner Chilcott Co Llc Enterische feste orale dosierform eines bisphosphonats mit einem chelate
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) * 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
EP0333082A3 (en) * 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
CA1336328C (en) * 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5018651A (en) * 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
TW237386B (es) * 1992-04-15 1995-01-01 Ciba Geigy
DK0646119T3 (da) * 1992-05-29 1998-12-14 Procter & Gamble Pharma Phosphonatforbindelser indeholdende kvaternært nitrogen til behandling af unormalt calcium- og phosphatstofskifte samt tan
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
CA2138366C (en) * 1992-06-30 1998-09-22 Kristine Hovancik Methods for the treatment of arthritis using phosphonates and nsaids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
JPH11506010A (ja) * 1995-06-07 1999-06-02 コドン・ゲーエムベーハー・ゲゼルシャフト・フュア・モレキュラーレ・メディツィーン・ウント・バイオテクノロジー 骨粗鬆症患者からの標準化された一次骨芽細胞培養物、および骨粗鬆症の診断および潜在的骨粗鬆症治療薬の試験におけるその使用
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
EP1088333A4 (en) * 1998-06-24 2005-08-10 Merck & Co Inc METHOD AND COMPOSITIONS FOR CONNECTING OSTEOPROSIS
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
PT1135140E (pt) * 1998-12-04 2005-10-31 Roche Diagnostics Gmbh Utilizacao de ibandronato para a promocao da integracao ossea de endoproteses
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
KR100863146B1 (ko) * 2000-07-17 2008-10-14 아스텔라스세이야쿠 가부시키가이샤 경구 흡수 개선 의약 조성물
EP1307206A2 (en) * 2000-07-19 2003-05-07 Eli Lilly And Company Method for enhancing bone mineral density gain by administration of raloxifene
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
BRPI0116865B8 (pt) * 2001-01-23 2021-05-25 Gador Sa composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
US7425549B2 (en) * 2001-02-06 2008-09-16 The Royal Alexandra Hospital For Children Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
JP4354698B2 (ja) * 2001-03-01 2009-10-28 エミスフェアー・テクノロジーズ・インク ビスホスホネートデリバリー用組成物
US6838584B2 (en) * 2001-05-10 2005-01-04 Merck & Co., Inc. Estrogen receptor modulators
US20030139378A1 (en) * 2001-12-13 2003-07-24 Daifotis Anastasia G. Liquid bisphosphonate formulations for bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
CN100479823C (zh) * 2001-12-21 2009-04-22 宝洁公司 双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
US20070166237A1 (en) 2007-07-19
MY147886A (en) 2013-01-31
JP2005514400A (ja) 2005-05-19
RU2294203C2 (ru) 2007-02-27
ZA200404007B (en) 2005-07-27
CZ2004690A3 (cs) 2004-09-15
EP1455796A1 (en) 2004-09-15
HK1087039A1 (en) 2006-10-06
WO2003055496A1 (en) 2003-07-10
SK2532004A3 (en) 2004-11-03
MA27157A1 (fr) 2005-01-03
CN1723024A (zh) 2006-01-18
HUP0402267A2 (hu) 2005-02-28
KR100638122B1 (ko) 2006-10-24
CA2469779C (en) 2008-02-12
CN100479823C (zh) 2009-04-22
PL371264A1 (en) 2005-06-13
US20080261924A1 (en) 2008-10-23
AU2002360619B2 (en) 2006-10-05
IL162053A (en) 2009-09-22
TWI349553B (en) 2011-10-01
US20030118634A1 (en) 2003-06-26
IL162053A0 (en) 2005-11-20
KR20040065283A (ko) 2004-07-21
AU2002360619A1 (en) 2003-07-15
US20080260827A1 (en) 2008-10-23
HUP0402267A3 (en) 2007-05-29
CA2469779A1 (en) 2003-07-10
AR038041A1 (es) 2004-12-22
NO340249B1 (no) 2017-03-27
NZ532994A (en) 2008-05-30
MXPA04006027A (es) 2004-09-27
NO20043113L (no) 2004-09-01
TW200301704A (en) 2003-07-16
US20080214505A1 (en) 2008-09-04
RU2004122433A (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
Zahrowski Bisphosphonate treatment: an orthodontic concern calling for a proactive approach
ES2532393T3 (es) Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
GB0029111D0 (en) Organic compounds
Yamashita et al. Antiresorptives and osteonecrosis of the jaw
Chacon et al. Effect of alendronate on endosseous implant integration: an in vivo study in rabbits
Zahrowski Optimizing orthodontic treatment in patients taking bisphosphonates for osteoporosis
RU2006140888A (ru) Лекарственные формы на основе бисфосфонатов
NO20053657L (no) Forbedrede formuleringer for transmukosal vaginal avlevering av bisfosfonater
NZ545804A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
PE20001082A1 (es) Composiciones que contienen acidos difosfonicos
PE20030743A1 (es) Metodo para el tratamiento de trastornos oseos
ES2269014T1 (es) Procedimiento para inhibir la resorcion osea.
HRP20041013B1 (hr) Formulacija visoke doze ibandronata
GB2411116A (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
Muniz et al. Effect of adjuvant bisphosphonates on treatment of periodontitis: Systematic review with meta-analyses
Suzuki et al. Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis
Camacho-Alonso et al. Cytoprotective effects of melatonin on zoledronic acid-treated human osteoblasts
DE60212621D1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
Gibreel et al. Osseointegration of dental implants and osteoporosis
Sidhu Drug induced orthodontic tooth movement
EA201001097A1 (ru) Фармацевтическая композиция для профилактики и лечения резорбции костной ткани различной этиологии
BR0106601A (pt) Composição farmacêutica contendo bisfosfonato para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, seu uso na preparação de medicamento para o tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato, método de tratamento de doenças relacionadas ao metabolismo de cálcio e/ou fosfato
JP2004534048A (ja) 骨再吸収を阻害するための組成物および方法
Arafath The Effect of Bisphosphonate [Pamidronate] On Orthodontic Tooth Movement in Rabbits
WO2006133097A3 (en) Use of alternating amine and non-amine bisphosphonate combinations for treating osteoporosis

Legal Events

Date Code Title Description
FC Refusal